Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877160 | 0.76 | ERN1 (0.61) | ERN1PTPN1PRKDCCYP2A6CYP3A4 | |
| SCHEMBL6900735 | 0.76 | ERN1 (0.61) | ERN1PTPN1PRKDCCYP2A6CYP3A4 | |
| SCHEMBL10496045 | 0.74 | ERN1 (0.59) | ERN1PTPN1PRKDCCYP2A6CYP3A4 | |
| SCHEMBL3189217 | 0.74 | TDP1 (0.47) | ERN1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL285148 | 0.73 | ERN1 (0.57) | ERN1PTPN1PRKDCCYP2A6CYP3A4 | |
| SCHEMBL1592418 | 0.73 | ERN1 (0.57) | ERN1PTPN1PRKDCCYP2A6CYP3A4 | |
| SCHEMBL2120180 | 0.73 | ERN1 (1.00) | ERN1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL29371317 | 0.73 | ERN1 (1.00) | ERN1CYP3A4TSHRTDP1LMNA | |
| SCHEMBL27987006 | 0.73 | ERN1 (0.57) | ERN1PTPN1PRKDCCYP2A6CYP3A4 | |
| SCHEMBL29353535 | 0.73 | ERN1 (0.57) | ERN1PTPN1PRKDCCYP2A6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2019152955-A9 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | EVERETT STEVEN ALBERT (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2019152955-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152911-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | ERN1 2708/4885PTPN1 1903/4885PRKDC 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.